Navigation Links
Neuroprotection - Drugs, Markets and Companies - Updated 2013 Report with Extra Company Collaborations
Date:8/9/2013

DUBLIN, August 9, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5f7vxx/neuroprotection) have announced the addition of a new report "Neuroprotection - Drugs, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products.

Pathomechanisms of diseases are described with steps at which neuroprotective therapies are directed. Diseases covered include cerebrovascular disorders, traumatic brain injury, spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and ischemic optic neuropathy as well as retinal degeneration. Although anesthetics such as propofol are neuroprotective as well, neuroprotection during surgery and anesthesia is discussed with the aim of preventing and treating complications that result in CNS damage.

The report contains profiles of 136 companies that have a neuroprotective product or products along with 120 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search of the literature was performed and selected 1,000 references are included. Clinical trials of various neuroprotective agents are described and failures of trials are analyzed with suggestions for improving the selection of drugs and design of trials. The report is supplemented with 67 tables and 13 figures.

Market analysis of currently used products that have a neuroprotective effect are analyzed for the year 2012. Some of these products are approved for other indications but are known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2017 when it will constitute a major and important component of the CNS market. Forecasts are made until 2022. By that time neuroprotection will be an established part of the neurological practice and measures will be available to achieve this effectively.

Key Topics Covered:

Part I: Drugs & Markets

Executive Summary

1. Introduction
2. Neuroprotective Agents
3. Neuroprotection in Cerebrovascular Disease
4. Neuroprotection in Traumatic Brain Injury
5. Neuroprotection in Spinal Cord Injury
6. Neuroprotection in Neurodegenerative Disorders
7. Neuroprotection in Parkinson Disease
8. Neuroprotection in Alzheimer Disease
9. Neuroprotection in Huntington Disease
10. Neuroprotection in Amyotrophic Lateral Sclerosis
11. Neuroprotection in Miscellaneous Neurological Disorders
12. Neuroprotection of the Optic nerve and the Retina
13. Neuroprotection during Anesthesia and Surgery
14. Markets for Neuroprotective Therapies
15. References

Part II: Companies

16. Companies Developing Neuroprotective Therapies

For more information visit http://www.researchandmarkets.com/research/5f7vxx/neuroprotection

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Biotechnology


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Alzheimer Disease - New Drugs, Markets and Companies - 2013
2. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
3. RNAi - Technologies, Markets and Companies - Updated 2012 Report
4. Life Science Software - 2013 Market Report: Markets and Opportunities
5. Cytogenetics - Technologies, Markets and Companies - 2013
6. Biomarkers - Technologies, Markets and Companies - Updated 2012 Report
7. Molecular Diagnostics: Technologies, Markets and Companies - 2013 Report
8. Next Generation Sequencing: Emerging Clinical Applications and Global Markets
9. Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles
10. OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
11. DNA Sequencing: Technologies, Markets and Companies - 2013 Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):